Open AccessPlasma Pharmacokinetic Parameters of Dexamethasone Following Administration of a Dexamethasone Intracanalicular Insert in Healthy Adults
Author(s) -
Charles D Blizzard,
Eugene McLaurin,
Arthur Driscoll,
Fabiana Q Silva,
Srilatha Vantipalli,
Jamie Lynne Metzinger,
Michael H. Goldstein
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s307194
Subject(s) - dexamethasone , medicine , cmax , pharmacokinetics , fundus (uterus) , intraocular pressure , ophthalmology , visual acuity , corticosteroid , anesthesia , surgery , pharmacology
Intracanalicular dexamethasone insert is a resorbable sustained-release polyethylene glycol-based hydrogel insert delivering a 0.4 mg tapered dose of dexamethasone for up to 30 days to the ocular surface. It is FDA-approved for treating inflammation and pain after ocular surgery. It has also been studied for ocular surface diseases such as allergic conjunctivitis. This study assessed the plasma pharmacokinetic (PK) parameters of dexamethasone following intracanalicular insertion.